Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B7 H3 SADA

Next Previous
Drug Profile

B7 H3 SADA

Alternative Names: B7-H3 SADA; B7-H3 SADA - Y-mAbs Therapeutics

Latest Information Update: 19 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts Institute of Technology; Memorial Sloan-Kettering Cancer Center
  • Developer Y-mAbs Therapeutics
  • Class Antibodies; Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Apoptosis stimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 19 Mar 2024 Preclinical development is ongoing in USA (parenteral) (Y-mAbs Therapeutics pipeline, March 2024)
  • 27 Jan 2021 Y-mAbs Therapeutics plans to submit IND for B7 H3 SADA in 2025 (Y-mAbs Therapeutics pipeline, March 2024)
  • 27 Jan 2021 Y-mAbs Therapeutics plans a clinical trial for Prostate cancer (Parenteral) (Y-mAbs Therapeutics pipeline, January 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top